Autobahn Therapeutics is a biotechnology company focused on developing next-generation regenerative medicines for CNS disorders. The company leverages a brain-targeting chemistry platform to create orally administered small molecule prodrugs, aiming to restore the brain to a healthier state and address the progressive nature of CNS conditions. Their lead product, ABX-002, is being developed for major depressive disorder and bipolar depression, with a strong emphasis on biomarker-driven development and validated human biology to de-risk their pipeline. With a world-class team and significant backing from investors, Autobahn is positioned to make a meaningful impact in the CNS therapeutic landscape.

San Diego, CA, USA

Autobahn Therapeutics

Therapeutics

S32 is a venture capital fund founded by Bill Maris.

Section 32, LLC

Tell us about your professional DNA to get discovered by any company in our network with opportunities relevant to your career goals.

Leverage our network to build your career.

#### Welcome!

Thank you for joining Section 32 Network!

To help us best support you in your search, please take a few minutes to tell us about what you are looking for in your next role. We’ll use this information to connect you to relevant opportunities in the Section 32 network as they come up.

You can always update this information later.

Welcome to the Section 32 talent network

As our companies grow, they look to us to help them find the best talent.

Signal that you'd be interested in working with a Section 32 company to help us put the right opportunities at great companies on your radar. The choice to pursue a new career move is then up to you.

Your professional information is now visible to our team and companies in our network.
We will be in touch when we find a great opportunity for you at one of our companies.

Thanks for signing up

As our companies grow, they look to us to help them find the best talent.
Signal that you'd be interested in working with a Section 32 company to help us put the right opportunities at great companies on your radar. The choice to pursue a new career move is then up to you.